205 related articles for article (PubMed ID: 36471401)
1. Quantification of DNA methylation for carcinogenic risk estimation in patients with non-alcoholic steatohepatitis.
Kuramoto J; Arai E; Fujimoto M; Tian Y; Yamada Y; Yotani T; Makiuchi S; Tsuda N; Ojima H; Fukai M; Seki Y; Kasama K; Funahashi N; Udagawa H; Nammo T; Yasuda K; Taketomi A; Kanto T; Kanai Y
Clin Epigenetics; 2022 Dec; 14(1):168. PubMed ID: 36471401
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide DNA methylation analysis during non-alcoholic steatohepatitis-related multistage hepatocarcinogenesis: comparison with hepatitis virus-related carcinogenesis.
Kuramoto J; Arai E; Tian Y; Funahashi N; Hiramoto M; Nammo T; Nozaki Y; Takahashi Y; Ito N; Shibuya A; Ojima H; Sukeda A; Seki Y; Kasama K; Yasuda K; Kanai Y
Carcinogenesis; 2017 Mar; 38(3):261-270. PubMed ID: 28426876
[TBL] [Abstract][Full Text] [Related]
3. Aberrant DNA methylation results in altered gene expression in non-alcoholic steatohepatitis-related hepatocellular carcinomas.
Tian Y; Arai E; Makiuchi S; Tsuda N; Kuramoto J; Ohara K; Takahashi Y; Ito N; Ojima H; Hiraoka N; Gotoh M; Yoshida T; Kanai Y
J Cancer Res Clin Oncol; 2020 Oct; 146(10):2461-2477. PubMed ID: 32685988
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation status of the SPHK1 and LTB genes underlies the clinicopathological diversity of non-alcoholic steatohepatitis-related hepatocellular carcinomas.
Tsuda N; Tian Y; Fujimoto M; Kuramoto J; Makiuchi S; Ojima H; Gotoh M; Hiraoka N; Yoshida T; Kanai Y; Arai E
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5109-5125. PubMed ID: 36348017
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathological approach to cancer epigenomics and its clinical application.
Kanai Y
Pathol Int; 2024 Apr; 74(4):167-186. PubMed ID: 38482965
[TBL] [Abstract][Full Text] [Related]
6. Human liver epigenetic alterations in non-alcoholic steatohepatitis are related to insulin action.
de Mello VD; Matte A; Perfilyev A; Männistö V; Rönn T; Nilsson E; Käkelä P; Ling C; Pihlajamäki J
Epigenetics; 2017 Apr; 12(4):287-295. PubMed ID: 28277977
[TBL] [Abstract][Full Text] [Related]
7. Carcinogenetic risk estimation based on quantification of DNA methylation levels in liver tissue at the precancerous stage.
Nagashio R; Arai E; Ojima H; Kosuge T; Kondo Y; Kanai Y
Int J Cancer; 2011 Sep; 129(5):1170-9. PubMed ID: 21400512
[TBL] [Abstract][Full Text] [Related]
8. Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model.
Padilla J; Osman NM; Bissig-Choisat B; Grimm SL; Qin X; Major AM; Yang L; Lopez-Terrada D; Coarfa C; Li F; Bissig KD; Moore DD; Fu L
J Hepatol; 2024 Feb; 80(2):282-292. PubMed ID: 37890720
[TBL] [Abstract][Full Text] [Related]
9. Silencing of microRNA-122 is an early event during hepatocarcinogenesis from non-alcoholic steatohepatitis.
Takaki Y; Saito Y; Takasugi A; Toshimitsu K; Yamada S; Muramatsu T; Kimura M; Sugiyama K; Suzuki H; Arai E; Ojima H; Kanai Y; Saito H
Cancer Sci; 2014 Oct; 105(10):1254-60. PubMed ID: 25117675
[TBL] [Abstract][Full Text] [Related]
10. Activation of apoptosis inhibitor of macrophage is a sensitive diagnostic marker for NASH-associated hepatocellular carcinoma.
Koyama N; Yamazaki T; Kanetsuki Y; Hirota J; Asai T; Mitsumoto Y; Mizuno M; Shima T; Kanbara Y; Arai S; Miyazaki T; Okanoue T
J Gastroenterol; 2018 Jun; 53(6):770-779. PubMed ID: 29086016
[TBL] [Abstract][Full Text] [Related]
11. Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Feng G; Li XP; Niu CY; Liu ML; Yan QQ; Fan LP; Li Y; Zhang KL; Gao J; Qian MR; He N; Mi M
Gene; 2020 Jun; 742():144549. PubMed ID: 32184169
[TBL] [Abstract][Full Text] [Related]
12. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma.
Kumar R; Goh BG; Kam JW; Chang PE; Tan CK
Clin Mol Hepatol; 2020 Apr; 26(2):196-208. PubMed ID: 31914720
[TBL] [Abstract][Full Text] [Related]
13. Oncostatin M is overexpressed in NASH-related hepatocellular carcinoma and promotes cancer cell invasiveness and angiogenesis.
Di Maira G; Foglia B; Napione L; Turato C; Maggiora M; Sutti S; Novo E; Alvaro M; Autelli R; Colombatto S; Bussolino F; Carucci P; Gaia S; Rosso C; Biasiolo A; Pontisso P; Bugianesi E; Albano E; Marra F; Parola M; Cannito S
J Pathol; 2022 May; 257(1):82-95. PubMed ID: 35064579
[TBL] [Abstract][Full Text] [Related]
14. Establishment of permutation for cancer risk estimation in the urothelium based on genome-wide DNA methylation analysis.
Tsumura K; Arai E; Tian Y; Shibuya A; Nishihara H; Yotani T; Yamada Y; Takahashi Y; Maeshima AM; Fujimoto H; Nakagawa T; Kume H; Homma Y; Yoshida T; Kanai Y
Carcinogenesis; 2019 Nov; 40(11):1308-1319. PubMed ID: 31241739
[TBL] [Abstract][Full Text] [Related]
15. Accumulation of 8-hydroxydeoxyguanosine, L-arginine and Glucose Metabolites by Liver Tumor Cells Are the Important Characteristic Features of Metabolic Syndrome and Non-Alcoholic Steatohepatitis-Associated Hepatocarcinogenesis.
Kakehashi A; Suzuki S; Ishii N; Okuno T; Kuwae Y; Fujioka M; Gi M; Stefanov V; Wanibuchi H
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33092030
[TBL] [Abstract][Full Text] [Related]
16. Different roles of FAT10, FOXO1, and ADRA2A in hepatocellular carcinoma tumorigenesis in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).
Jia Y; French B; Tillman B; French S
Exp Mol Pathol; 2018 Aug; 105(1):144-149. PubMed ID: 30009772
[TBL] [Abstract][Full Text] [Related]
17. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.
Pinyol R; Torrecilla S; Wang H; Montironi C; Piqué-Gili M; Torres-Martin M; Wei-Qiang L; Willoughby CE; Ramadori P; Andreu-Oller C; Taik P; Lee YA; Moeini A; Peix J; Faure-Dupuy S; Riedl T; Schuehle S; Oliveira CP; Alves VA; Boffetta P; Lachenmayer A; Roessler S; Minguez B; Schirmacher P; Dufour JF; Thung SN; Reeves HL; Carrilho FJ; Chang C; Uzilov AV; Heikenwalder M; Sanyal A; Friedman SL; Sia D; Llovet JM
J Hepatol; 2021 Oct; 75(4):865-878. PubMed ID: 33992698
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide DNA methylation profiles in liver tissue at the precancerous stage and in hepatocellular carcinoma.
Arai E; Ushijima S; Gotoh M; Ojima H; Kosuge T; Hosoda F; Shibata T; Kondo T; Yokoi S; Imoto I; Inazawa J; Hirohashi S; Kanai Y
Int J Cancer; 2009 Dec; 125(12):2854-62. PubMed ID: 19569176
[TBL] [Abstract][Full Text] [Related]
19. Supervised learning reveals circulating biomarker levels diagnostic of hepatocellular carcinoma in a clinically relevant model of non-alcoholic steatohepatitis; An OAD to NASH.
Hwang A; Shi C; Zhu E; Naaz F; Zhou P; Rasheed Z; Liu M; Jung LS; Duan B; Li J; Jiang K; Paka L; Gadhiya SV; Dana D; Ali Q; Yamin MA; Goldberg ID; Narayan P
PLoS One; 2018; 13(6):e0198937. PubMed ID: 29944670
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation alterations of ADCY5, MICAL2, and PLEKHG2 during the developmental stage of cryptogenic hepatocellular carcinoma.
Makiuchi S; Tian Y; Fujimoto M; Kuramoto J; Tsuda N; Ojima H; Gotoh M; Hiraoka N; Yoshida T; Kanai Y; Arai E
Hepatol Res; 2024 Mar; 54(3):284-299. PubMed ID: 37906571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
